Search

Your search keyword '"Razin, VA"' showing total 22 results
Start Over Author "Razin, VA"
22 results on '"Razin, VA"'

10. The Sky Polarization Observatory

Author

Cortiglioni, S, Bernardi, G, Carretti, E, Casarini, L, Cecchini, S, Macculi, C, Ramponi, M, Sbarra, C, Monari, J, Orfei, A, Poloni, M, Poppi, S, Boella, G, Bonometto, S, Colombo, L, Gervasi, M, Sironi, G, Zannoni, M, Baralis, M, Peverini, O, Tascone, R, Virone, G, Fabbri, R, Natale, V, Nicastro, L, Ng, K, Vinyajkin, E, Razin, V, Sazhin, M, Strukov, I, Negri, B, Peverini, OA, Ng, K. W, Vinyajkin, EN, Razin, VA, Sazhin, MV, Strukov, IA, Negri, B., BOELLA, GIULIANO FILIPPO, BONOMETTO, SILVIO, GERVASI, MASSIMO, SIRONI, GIORGIO, ZANNONI, MARIO, Cortiglioni, S, Bernardi, G, Carretti, E, Casarini, L, Cecchini, S, Macculi, C, Ramponi, M, Sbarra, C, Monari, J, Orfei, A, Poloni, M, Poppi, S, Boella, G, Bonometto, S, Colombo, L, Gervasi, M, Sironi, G, Zannoni, M, Baralis, M, Peverini, O, Tascone, R, Virone, G, Fabbri, R, Natale, V, Nicastro, L, Ng, K, Vinyajkin, E, Razin, V, Sazhin, M, Strukov, I, Negri, B, Peverini, OA, Ng, K. W, Vinyajkin, EN, Razin, VA, Sazhin, MV, Strukov, IA, Negri, B., BOELLA, GIULIANO FILIPPO, BONOMETTO, SILVIO, GERVASI, MASSIMO, SIRONI, GIORGIO, and ZANNONI, MARIO

Abstract

The Sky Polarization Observatory (SPOrt) is an ASI-funded experiment specifically designed to measure the sky polarization at 22, 32 and 90 GHz, which was selected in 1997 by ESA to be flown on the International Space Station. Starting in 2006 and for at least 18 months, it will be taking direct and simultaneous measurements of the Stokes parameters Q and U at 660 sky pixels, with FWHM=7°. Due to development efforts over the past few years, the design specifications have been significantly improved with respect to the first proposal. Here we present an up-to-date description of the instrument, which now warrants a pixel sensitivity of 1.7 K for the polarization of the cosmic background radiation, assuming two years of observations. We discuss SPOrt scientific goals in the light of WMAP results, in particular in connection with the emerging double-reionization cosmological scenario.

Published
2004

11. SPOrt: An experiment aimed at measuring the large scale cosmic microwave background polarization

Author

Fineschi S., Carretti, E, Cortiglioni, S, Bernardi, G, Cecchini, S, Macculi, C, Sbarra, C, Monari, J, Orfei, A, Poloni, M, Poppi, S, Boella, G, Bonometto, S, Gervasi, M, Sironi, G, Zannoni, M, Tucci, M, Baralis, M, Peverini, O, Tascone, R, Virone, G, Fabbri, R, Nicastro, L, Ng, K, Razin, V, Vinyajkin, E, Sazhin, M, Strukov, I, BOELLA, GIULIANO FILIPPO, BONOMETTO, SILVIO, GERVASI, MASSIMO, SIRONI, GIORGIO, ZANNONI, MARIO, Peverini, OA, Ng, KW, Razin, VA, Vinyajkin, EN, Sazhin, MV, Strukov, IA, Fineschi S., Carretti, E, Cortiglioni, S, Bernardi, G, Cecchini, S, Macculi, C, Sbarra, C, Monari, J, Orfei, A, Poloni, M, Poppi, S, Boella, G, Bonometto, S, Gervasi, M, Sironi, G, Zannoni, M, Tucci, M, Baralis, M, Peverini, O, Tascone, R, Virone, G, Fabbri, R, Nicastro, L, Ng, K, Razin, V, Vinyajkin, E, Sazhin, M, Strukov, I, BOELLA, GIULIANO FILIPPO, BONOMETTO, SILVIO, GERVASI, MASSIMO, SIRONI, GIORGIO, ZANNONI, MARIO, Peverini, OA, Ng, KW, Razin, VA, Vinyajkin, EN, Sazhin, MV, and Strukov, IA

Published
2003

13. P248 Markers of interstitial fibrosis in hypertensive patients with left ventricle hypertrophy.

Author

Krestjyaninov, MV, Razin, VA, and Gimaev, RH

Subjects
*BIOMARKERS, *PULMONARY fibrosis, *HYPERTENSION, *PATIENTS, *HYPERTROPHY, *STROKE, *MYOCARDIAL infarction
Abstract

It′s well known that left ventricle (LV) geometry type is strongly associated with stroke and myocardial infarction in hypertensive patients. The most negative prognosis have persons with concentric hypertrophy of LV and concentric remodelling of LV. Both cardiomyocytes and extracellular matrix are involved in left ventricle remodelling process and their ratio determine disorders of left ventricle function and structure which result in complications.The purpose of the study is to evaluate levels of plasma markers of myocardial fibrosis in hypertensive patients with different types of left ventricle geometry models.Materials and methods: Were examined 324 patients with arterial hypertension (AH) 2-3 grade and ischemic heart disease (stable angina 2-3 functional class) complicated by CHF I-III NYHA functional class. The mean age of patients - 77 (61; 84) years. Patients with arrhythmias, diabetes mellitus were excluded from the study. As control group were enrolled 42 healthy persons (mean age - 70 (17) years). In all patients was performed ECG in 12 standard leads, EchoCG (ASE/EAE recommendations 2005) and were evaluated plasma levels of aldosteron, tissue inhibitor of metalloproteinases-1 (TIMP-1) and Insulin-like growth factor 1 (IGF-1).Statistical significance was defined at the level of methods for p<0,05.Results: As it can be seen from Table 1 The values of aldosteron (which known as interstitial fibrosis trigger) and TIMP-1 (plasma marker of interstitial fibrosis) were significant higher in patients with concentric hypertrophy and eccentric hypertrophy in comparison with hypertensive patients with normal geometry of LV and healthy persons.Conclusion: Thus, the results of the study show that levels of plasma markers of interstitial myocardial fibrosis indicate higher levels of interstitial fibrosis in hypertensive patients with such geometric models of left ventricle as concentric hypertrophy and concentric remodelling.Markers of interstitial fibrosis & LVHParametersHypertensive patientsHealthy persons with normal geometry of LV n=42Normal geometry n=57Concentric remodelling n=32Concentric hypertrophy n=166Eccentric hypertrophy n=99Aldosteron (pg/ml)121.54 (27.51)*95.8 (43.41)143.19 (38.95)*†144.5 (38.25)*†72.82 (31.39)TIMP-1 (ng/ml)276.91 (80.32)*249.82 (83.23)*403.13 (128.53)*†359.93 (119.54)*†103.44 (7.06)IGF-1 (ng/ml)162.56 (23.55)158.29 (18.91)155.51 (24.45)139.88 (19.74)*154.63 (21.69)Results are shown in M (SD).*- p<0.05 in comparison with healthy persons, †- p<0.05 in comparison with patients with normal geometry of LV [ABSTRACT FROM PUBLISHER]

Published
2014
Full Text
View/download PDF

14. P570 AT2P1 gene polymorphism effect on development of arrhythmias in hypertensive patients.

Author

Krestjyaninov, MV, Gimaev, RH, Razin, VA, Melnikova, MA, and Olezov, NV

Subjects
GENETIC polymorphisms, ARRHYTHMIA, HYPERTENSION, PATIENTS, HEART physiology, RENIN-angiotensin system, ANGIOTENSIN receptors
Abstract

Arrhythmias development determined by structural alterations of the heart, renin-angiotensin system activity and genetic factors.The purpose of our study was to evaluate angiotensin 2 receptor type 1 (AT2P1) gene polymorphism effect on development of arrhythmias in hypertensive patients.Were examined 125 patients with arterial hypertension (AH) 1-3 grade complicated by HF I-II NYHA functional class. The mean age of patients - 52.2 (6.8) years. Patients with acute myocardial infarction in history, diabetes mellitus and autoimmune diseases were excluded from the study. In all patients was performed ECG in 12 standard leads, Holter ECG monitoring, EchoCG (ASE/EAE recommendations 2005). HF NYHA functional class was determined by using the 6MWT. Extrasystoles types were determined by Lown B. classification. Genotyping of AT2P1 gene was performed by polymerase chain reaction analysis of DNA restriction fragments length.Statistical significance was defined at the level of methods for p<0,05.As it can be seen from Table 1 the presence of C allele in genotype of AT2P1 gene accompanied by a statistically significant increase of the frequency of high grade ventricular extrasystoles in comparison with homozygous AA type: 5 patients (7%) with AA and 9 patients (20%) with AC: Chi2 =3.8, p= 0.048, RR= 2.8 (95%CI 1.06 - 7.9).Thus, results of our study indicates role of C allele in genotype of AT2P1 gene in development of high grade ventricular extrasystoles in hypertensive patients.AT2P1 gene polymorphism & arrhythmiasGenotypeArrhythmia typeAA n=71AC n=44CC n=10n (%)n (%)n (%)all SVPB45 (63%)33 (75%)7 (70%) Rare SVPB33 (46%)19 (43%)4 (40%) Frequent SVPB12 (17%)14 (32%)3 (30%)Paroxysmal AF7 (10%)5 (11%)-Supraventricular tachycardia4 (6%)3 (5%)1 (10%)all ventricular extrasystoles26 (37%)21 (48%)6 (60%) Rare ventricular extrasystoles19 (27%)15 (34%)4 (40%) Frequent ventricular extrasystoles7 (10%)6 (14%)2 (20%) Ventricular extrasystole 3-4 grade5 (7%)9 (20%)2 (20%)SVPB - supraventricular premature beats, AF - atrial fibrillation [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

15. Club 35 Poster session 1: Wednesday 3 December 2014, 09:00-16:00 * Location: Poster area

Author

Krestjyaninov, MV, Gimaev, RH, Razin, VA, Halaph, H, Shameeva, OV, Galli, E, Oger, E, Levery, M, Mabo, P, Donal, E, Rodriguez Munoz, D, Carbonell Sanroman, A, Moya Mur, JL, Lazaro Rivera, C, Fernandez Santos, S, Rincon Diaz, LM, Casas Rojo, E, Jimenez Nacher, JJ, Fernandez-Golfin, C, Zamorano Gomez, JL, Shamsheva, D, Zaletova, T, Parkhomenko, O, Bogdanov, A, Simova, I, Katova, T, Galderisi, M, Pauncheva, B, Ozawa, K, Funabashi, N, Takaoka, H, Kobayashi, Y, Titov, I, Kovalenko, V, Nesukay, E, Danylenko, O, Polenova, N, Moatemri, F, Messaoudi, Y, Mahdhaoui, A, Bouraoui, H, Hajri, S, Jeridi, G, Danylenko, O, Kovalenko, V, Nesukay, E, Polenova, N, Titov, I, Souza, C, Nascimento, CAS, Cordovil, IP, Belem, LJH, Horcades, RF, Sahate, AS, Pereira, SB, Benchimol-Barbosa, PR, Barros, CN, Weitzel, LH, Altin, C, Sade, LE, Gezmis, E, Ozen, N, Muderrisoglu, H, Voilliot, D, Magne, JM, Dulgheru, RD, Kou, SK, Henri, CH, Caballero, LC, De Sousa, CDS, Sprynger, MS, Pierard, LP, Lancellotti, PL, Miglioranza, MH, Mihaila, S, Muraru, D, Cucchini, U, Cecchetto, A, Cavalli, G, Romeo, G, Iliceto, S, Badano, LP, Brecht, A, Wageloehner, T, Oertelt-Prigione, S, Seeland, U, Ruecke, M, Baumann, G, Regitz-Zagrosek, V, Stangl, V, Knebel, F, Investigators, BEFRI, Khanna, R, Raghuwanshi, A, Kapoor, A, Tewari, S, Garg, N, Kumar, S, Goel, PK, Altin, C, Sade, LE, Gezmis, E, Ozen, N, Duzceker, O, Muderrisoglu, H, Petre, I, Tautu, OF, Onciul, S, Iancovici, S, Zamfir, D, Onut, R, Dorobantu, M, Jashari, F, Ibrahimi, P, Johansson, E, Gronlund, C, Bajraktari, G, Wester, P, Henein, MY, Torbas, O, Sirenko, YU, Radchenko, G, Page, M, Gerber, BL, Pasquet, A, Pouleur, AC, Vancreynest, D, Vanoverschelde, JL, Wieczorek, J, Wieczorek, P, Mizia, M, Gieszczyk-Strozik, K, Sikora-Puz, A, Lasota, B, Mizia-Stec, K, Coisne, A, Levy, F, Malaquin, D, Richardson, M, Quere, JP, Montaigne, D, Tribouilloy, C, Teixeira, R, Monteiro, R, Barbosa, A, Batista, R, Ribeiro, M, Cardim, N, Goncalves, L, Miskowiec, D, Wierzbowska-Drabik, K, Wejner-Mik, P, Michalski, B, Wdowiak-Okrojek, K, Szymczyk, E, Kasprzak, JD, Lipiec, P, Grossi, F, Oddo, A, Pieri, F, Cordisco, A, Zucchini, M, Mori, F, and Gensini, GF

Abstract

Left ventricle hypertrophy (LVH) is strongly associated with stroke and myocardial infarction in hypertensive patients. Hypertensive heart characterized by cardiomyocytes hypertrophy, fibroblasts proliferation, enlargement of interstitial collagen volume and their ratio disorders which result in dangerous complications. Renin-angiotensin-aldosterone system (RAAS) and insulin-like growth factor 1 (IGF-1) play significant role in development of myocardial fibrosis and LV remodelling in hypertensive patients. The purpose of the study is to evaluate relations between activity of RAAS and interstitial fibrosis markers and left ventricle geometry models in hypertensive patients. Were examined 286 patients (both men and women) with Hypertension 2-3 grade and stable ischemic heart disease 2-3 functional class complicated by chronic heart failure I-III NYHA functional class. The mean age of patients 53 (3.7) years. Patients with arrhythmias, diabetes mellitus were excluded from the study. In all patients was performed EchoCG (ASE/EAE recommendations 2005) and were evaluated plasma levels of aldosteron, angiotensin 2, angiotensin-converting enzyme (ACE), tissue inhibitor of metalloproteinases-1 (TIMP-1), IGF-1. HF NYHA functional class was determined by using the 6MWT. Statistical significance was defined at the level of methods for p<0,05. Results of the study are shown in Table 1. Thus, the results of the study show that interstitial myocardium fibrosis and activity of RAAS were significantly higher in patients with concentric hypertrophy and eccentric hypertrophy. LV remodelling, RAAS and fibrosis ParametersLV geometry modelNormal geometryConcentric remodellingEccentric hypertrophyConcentric hypertrophyn=148n=36n=50n=52Angiothensin 2, pg/ml37.8 (11.6)39.0 (16.4)47.4 (13.4)57.7 (10.5)*†ACE, u/l45.8 (16.7)38.9 (17.1)62.5 (35.3)*73.8 (25.9)*Aldosterone, pg/ml121.5 (27.5)95.8 (43.4)144.5 (38.3)*143.2 (38.9)*TIMP-1, ng/ml276.9 (80.3)249.8 (83.2)359.9 (119.5)*‡403.1 (128.5)*‡IGF-1, ng/ml162.6 (23.6)†158.3 (18.9)†139.9 (19.7)155.5 (24.5)†Interstitial collagen volume fraction, %3.03 (0.78)3.66 (0.96)*4.47 (0.98)*‡5.34 (0.97)*†‡ *- p<0.05 in comparison with patients with normal geometry; † - p<0.05 in comparison with patients with eccentric hypertrophy; ‡ - p<0.05 in comparison with patients with concentric remodelling. Results are shown in M (SD).

Published
2014
Full Text
View/download PDF

16. Club35 Poster Session Thursday 12 December: 12/12/2013, 08:30-18:00 * Location: Poster area

Author

Montoro Lopez, M, Iniesta Manjavacas, AM, Mori Junco, R, Pena Conde, L, Pons De Antonio, I, Garcia Blas, S, Lopez Fernandez, T, Moreno Gomez, R, Moreno Yanguela, M, Lopez Sendon, JL, Carro, A, Kiotsekoglou, A, Andoh, J, Brown, S, Kaski, JC, Imamura, Y, Arai, K, Uematsu, S, Fukushima, K, Hoshi, H, Ashihara, K, Takagi, A, Hagiwara, N, Gillis, K, Bala, G, Roosens, B, Remory, I, Droogmans, S, Van Camp, G, Cosyns, B, Van De Heyning, CM, Magne, J, Pierard, LA, Bruyere, PJ, Davin, L, De Maeyer, C, Paelinck, BP, Vrints, CJ, Lancellotti, P, Borowiec, A, Dabrowski, R, Kowalik, I, Firek, B, Chwyczko, T, Janas, J, Szwed, H, Tufaro, V, Fragasso, G, Ingallina, G, Marini, C, Fisicaro, A, Loiacono, F, Margonato, A, Agricola, E, Ferreira, F, Pereira, TS, Abreu, J, Labandeiro, J, Fiarresga, A, Ferreira, AM, Galrinho, A, Branco, LM, Timoteo, AT, Ferreira, RC, Marmol, R, Gomez, M, Garcia, K, Sanmiguel, D, Cabades, C, Monteagudo, M, Nunez, C, Fernandez, C, Diez, JL, Roldan, I, Kolesnyk, MY, Borowiec, A, Dabrowski, R, Kowalik, I, Firek, B, Chwyczko, T, Janas, J, Szwed, H, Marini, C, Tufaro, V, Ancona, MB, Fisicaro, A, Oppizzi, M, Margonato, A, Agricola, E, Krestjyaninov, M, Razin, VA, Gimaev, RH, Carminati, MC, Piazzese, C, Tsang, W, Lang, RM, Caiani, EG, Goncalves, S, Ramalho, A, Placido, R, Marta, L, Cortez Dias, N, Magalhaes, A, Menezes, M, Martins, S, Almeida, A, Nunes Diogo, A, Stokke, T M, Ruddox, V, Sarvari, S I, Otterstad, J E, Aune, E, Edvardsen, T, Pirone, D, De Francesco, V, Marino, F, Gervasi, F, Demartini, C, Goffredo, C, Bono, MC, Mega, S, Chello, M, Di Sciascio, G, Martin Hidalgo, M, Seoane Garcia, T, Carrasco Avalos, F, Mesa Rubio, MD, Delgado Ortega, M, Ruiz Ortiz, M, Mazuelos Bellido, F, Suarez De Lezo Herrero De Tejada, J, Pan Alvarez De Osorio, M, Suarez De Lezo Cruz Conde, J, Seoane Garcia, T, Martin Hidalgo, M, Carrasco Avalos, F, Mesa Rubio, MD, Ruiz Ortiz, M, Delgado Ortega, M, Lopez Granados, A, Romero Moreno, M, Pan Alvarez-Ossorio, M, Suarez De Lezo Cruz Conde, J, Menichetti, F, Bongiorni, MG, Ferro, B, Segreti, L, Bertini, P, Mariotti, R, Baldassarri, R, Di Cori, A, Zucchelli, G, Guarracino, F, Santoro, A, Federco Alvino, FA, Giovanni Antonelli, GA, Raffaella De Vito, RDV, Roberta Molle, RM, Sergio Mondillo, SM, Mahmoud, Y, Abdel-Kader, M, Guindy, R, Elzahwy, S, Dijkema, EJ, Molenschot, MC, Slieker, MG, Oliveira Da Silva, C, Sahlen, A, Winter, R, Back, M, Ruck, A, Settergren, M, Manouras, A, Shahgaldi, K, Krestjyaninov, MV, and Ruzov, VI

Abstract

Purpose: The coexistence of mitral regurgitation (MR) and severe aortic stenosis is a common problem in elderly patients that limits the indication for percutaneous aortic prosthesis (TAVI). However, recent publications indicate a decrease in MR after TAVI because of the improvement of left ventricle (LV) hemodynamic conditions. The aim of our study was to investigate clinical and echocardiographic predictors of MR after TAVI. Methods: We included patients undergoing TAVI from May 2008 to November 2012. It was performed a 3D transesophageal echocardiogram during the procedure and a transthoracic echocardiogram before discharge and 12 months after implantation. We studied the etiology of MR before procedure, LV ejection fraction, chambers volume, pulmonary hypertension and tricuspid regurgitation, as well as clinical and technical variables related to the procedure. Results: 90 patients underwent TAVI successfully (Table). At the beginning, 21% of patients had MR at least grade III/IV. After TAVI, 84.4% of patients showed no change in MR degree, 12.2% improved and only 3.3% worsened. Variables related with MR worsening were rheumatic MR etiology, history of atrial fibrillation (AF) and the coexistence of significant tricuspid regurgitation (TR) in the baseline study (p <0.04, p <0.01; p <0.03, respectively). Conclusions: In patients undergoing TAVI, the rheumatic etiology of MR, the previous history of AF and significant TR coexistence were factors related to MR worsening after the procedure.   Baseline characteristics. N = 90Age81.9 ± 6.9Women49 (54.4%)LVEF56 % ± 11.6Previous stroke16 (18%)Previous AF36 (42.4%)Baseline creatinine serum level1.3 mg/dl ± 0.5EuroSCORE16.8 ± 9.2Transfemoral approach71 (79.8%)Transapical approach18 (20.2%) LVEF: ejection fraction of the left ventricle. AF: atrial fibrillation

Published
2013
Full Text
View/download PDF

17. Club 35 Poster Session Wednesday 11 December: 11/12/2013, 09:30-16:00 * Location: Poster area

Author

Montoro Lopez, M, Pons De Antonio, I, Itziar Soto, C, Florez Gomez, R, Alonso Ladreda, A, Rios Blanco, JJ, Refoyo Salicio, E, Moreno Yanguela, M, Lopez Sendon, JL, Guzman Martinez, G, Van De Heyning, C M, Magne, J, Pierard, LA, Bruyere, PJ, Davin, L, De Maeyer, C, Paelinck, BP, Vrints, CJ, Lancellotti, P, Michalski, BW, Krzeminska-Pakula, M, Lipiec, P, Szymczyk, E, Chrzanowski, L, Kasprzak, JD, Leao, R N, Florencio, A F, Oliveira, A R, Bento, B, Lopes, S, Calaca, J, Palma Reis, R, Krestjyaninov, MV, Gimaev, RH, Razin, VA, Arangalage, D, Chiampan, A, Cimadevilla, C, Touati, A, Himbert, D, Brochet, E, Iung, B, Nataf, P, Vahanian, A, Messika-Zeitoun, D, Guvenc, TS, Karacimen, D, Erer, HB, Ilhan, E, Sayar, N, Karakus, G, Eren, M, Iriart, X, Tafer, N, Roubertie, F, Mauriat, P, Thambo, JB, Wang, J, Fang, F, Yip, G WK, Sanderson, J, Feng, W, Yu, CM, Lam, YY, Assabiny, A, Apor, A, Nagy, A, Vago, H, Toth, A, Merkely, B, Kovacs, A, Castaldi, B, Vida, VL, Guariento, A, Padalino, M, Cerutti, A, Maschietto, N, Biffanti, R, Reffo, E, Stellin, G, Milanesi, O, Baronaite-Dudoniene, K, Urbaite, L, Smalinskas, V, Veisaite, R, Vasylius, T, Vaskelyte, J, Puodziukynas, A, Wieczorek, J, Rybicka-Musialik, A, Berger-Kucza, A, Hoffmann, A, Wnuk-Wojnar, A, Mizia-Stec, K, Melao, F, Ribeiro, V, Amorim, S, Araujo, C, Torres, JP, Cardoso, JS, Pinho, P, Maciel, MJ, Storsten, P, Eriksen, M, Boe, E, Estensen, ME, Erikssen, G, Smiseth, OA, Skulstad, H, Miglioranza, MH, Gargani, L, Sant`Anna, RT, Rover, M, Martins, VM, Mantovanni, A, Kalil, RK, Leiria, TL, Luo, XX, Fang, F, Lee, PW, Zhang, ZH, Lam, YY, Sanderson, JE, Kwong, J SW, Yu, CM, Borowiec, A, Dabrowski, R, Wozniak, J, Jasek, S, Chwyczko, T, Kowalik, I, Janas, J, Musiej-Nowakowska, E, Szwed, H, Palinsky, M, Petrovicova, J, Pirscova, M, Baricevic, Z, Lovric, D, Cikes, M, Skoric, B, Ljubas Macek, J, Reskovic Luksic, V, Separovic Hanzevacki, J, Milicic, D, Elmissiri, AM, El Shahid, GS, Abdal-Wahhab, S, Vural, M G, Yilmaz, M, Cetin, S, Akdemir, R, Yoldas, T K, Yeter, E, Karamanou, AG, Hamodraka, ES, Lekakis, IA, Paraskevaidis, IA, Kremastinos, DT, Appiah-Dwomoh, E K, Wang, VC, Otto, C, Mayar, F, Bonaventura, K, Sunman, H, Canpolat, U, Kuyumcu, M, Yorgun, H, Sahiner, L, and Ozer, N

Abstract

Purpose: It is known the higher prevalence of structural heart disease in HIV patients, mostly diastolic dysfunction and pulmonary hypertension. In spite of that, there are few data about predisposing factors. Our objective was to evaluate whether HIV stage or detectable blood viral load correlate with the degree of heart disease. Methods: We conducted a prospective cohort study with HIV patients monitored by the internal medicine unit of our institution. We selected symptomatic patients with functional class ≥ II of NYHA scale. Viral blood load and CD4 count were systematically determined in order to obtain the HIV stage. Patients underwent a transthoracic echocardiogram to assess ventricular hypertrophy, systolic and diastolic dysfunction and pulmonary hypertension, according to the limits set by ESC guidelines. Results: Data were obtained from 65 HIV patients with dyspnea (63% male) with a mean age of 48 years. 50% were in NYHA grade II, 32.3% III and 17.7% IV. 46.7% of patients had some data of structural heart disease (figure). Belong to AIDS group (65.3%) did not correlate with the degree of heart disease. However, patients with positive blood viral load had a significantly higher incidence of structural heart disease than those with undetectable load (75% vs. 43% p <0.04), independent of their cardiovascular risk profile or type of antiretroviral therapy (Table). Conclusion: In our experience, half of HIV patients with dyspnea show echocardiographic data of structural heart disease. Detectable viral load in blood doubles the prevalence of heart disease, so that HIV itself may be an independent causal agent. These data should be taken into account in the screening of structural heart disease in these patients. Figure Prevalence of structural heart disease

Published
2013
Full Text
View/download PDF

18. Poster session Wednesday 11 December all day display: 11/12/2013, 09:30-16:00 * Location: Poster area

Author

Bertrand, PB, Grieten, L, Smeets, C, Verbrugge, FH, Mullens, W, Vrolix, M, Rivero-Ayerza, M, Verhaert, D, Vandervoort, P, Tong, L, Ramalli, A, Tortoli, P, Dhoge, J, Bajraktari, G, Lindqvist, P, Henein, MY, Obremska, M, Boratynska, MB, Kurcz, JK, Zysko, DZ, Baran, TB, Klinger, MK, Darahim, K, Mueller, H, Carballo, D, Popova, N, Vallee, J-P, Floria, M, Chistol, R, Tinica, G, Grecu, M, Rodriguez Serrano, M, Osa-Saez, A, Rueda-Soriano, J, Buendia-Fuentes, F, Domingo-Valero, D, Igual-Munoz, B, Alonso-Fernandez, P, Quesada-Carmona, A, Miro-Palau, V, Palencia-Perez, M, Bech-Hanssen, O, Polte, CL, Lagerstrand, K, Janulewicz, M, Gao, S, Erdogan, E, Akkaya, M, Bacaksiz, A, Tasal, A, Sonmez, O, Turfan, M, Kul, S, Vatankulu, MA, Uyarel, H, Goktekin, O, Mincu, RI, Magda, LS, Mihaila, S, Florescu, M, Mihalcea, D, Enescu, OE, Chiru, A, Popescu, B, Tiu, C, Vinereanu, D, 112/2011, Research grant, Broch, K, Kunszt, G, Massey, R, De Marchi, SF, Aakhus, S, Gullestad, L, Urheim, S, Yuan, L, Feng, JL, Jin, XY, Bombardini, T, Casartelli, M, Simon, D, Gaspari, MG, Procaccio, F, Hasselberg, NE, Haugaa, KH, Brunet, A, Kongsgaard, E, Donal, E, Edvardsen, T, Sahin, TAYLAN, Yurdakul, S, Cengiz, BETUL, Bozkurt, AYSEN, Aytekin, SAIDE, Cesana, F, Spano, F, Santambrogio, G, Alloni, M, Vallerio, P, Salvetti, M, Carerj, S, Gaibazzi, N, Rigo, F, Moreo, A, Group, APRES Collaborative, Wdowiak-Okrojek, K, Michalski, B, Kasprzak, JD, Shim, A, Lipiec, P, Generati, G, Pellegrino, M, Bandera, F, Donghi, V, Alfonzetti, E, Guazzi, M, Marcun, R, Stankovic, I, Farkas, J, Vlahovic-Stipac, A, Putnikovic, B, Kadivec, S, Kosnik, M, Neskovic, AN, Lainscak, M, Iliuta, L, Szymanski, P, Lipczynska, M, Klisiewicz, A, Sobieszczanska-Malek, M, Zielinski, T, Hoffman, P, Gjerdalen, G F, Hisdal, J, Solberg, EE, Andersen, TE, Radunovic, Z, Steine, K, Svanadze, A, Poteshkina, N, Krylova, N, Mogutova, P, Shim, A, Kasprzak, JD, Szymczyk, E, Wdowiak-Okrojek, K, Michalski, B, Stefanczyk, L, Lipiec, P, Benedek, T, Matei, C, Jako, B, Suciu, ZS, Benedek, I, Yaroshchuk, N A, Kochmasheva, V V, Dityatev, V P, Kerbikov, O B, Przewlocka-Kosmala, M, Orda, A, Karolko, B, Mysiak, A, Kosmala, W, Rechcinski, T, Wierzbowska-Drabik, K, Lipiec, P, Chmiela, M, Kasprzak, JD, Aziz, A, Hooper, J, Rayasamudra, S, Uppal, H, Asghar, O, Potluri, R, Zaroui, A, Mourali, MS, Rezine, Z, Mbarki, S, Jemaa, M, Aloui, H, Mechmeche, R, Farhati, A, Gripari, P, Maffessanti, F, Tamborini, G, Muratori, M, Fusini, L, Vignati, C, Bartorelli, AL, Alamanni, F, Agostoni, PG, Pepi, M, Ruiz Ortiz, M, Mesa, D, Delgado, M, Seoane, T, Carrasco, F, Martin, M, Mazuelos, F, Suarez De Lezo Herreros De Tejada, J, Romero, M, Suarez De Lezo, J, Brili, S, Stamatopoulos, I, Misailidou, M, Chrisochoou, C, Christoforatou, E, Stefanadis, C, Ruiz Ortiz, M, Mesa, D, Delgado, M, Martin, M, Seoane, T, Carrasco, F, Ojeda, S, Segura, J, Pan, M, Suarez De Lezo, J, Cammalleri, V, Ussia, GP, Muscoli, S, Marchei, M, Sergi, D, Mazzotta, E, Romeo, F, Igual Munoz, B, Bel Minguez, ABM, Perez Guillen, MPG, Maceira Gonzalez, AMG, Monmeneu Menadas, JVMM, Hernandez Acuna, CHA, Estornell Erill, JEE, Lopez Lereu, PLL, Francisco Jose Valera Martinez, FJVM, Montero Argudo, AMA, Sunbul, M, Akhundova, A, Sari, I, Erdogan, O, Mutlu, B, Cacicedo, A, Velasco Del Castillo, S, Anton Ladislao, A, Aguirre Larracoechea, U, Rodriguez Sanchez, I, Subinas Elorriaga, A, Oria Gonzalez, G, Onaindia Gandarias, J, Laraudogoitia Zaldumbide, E, Lekuona Goya, I, Ding, W, Zhao, Y, Lindqvist, P, Nilson, J, Winter, R, Holmgren, A, Ruck, A, Henein, MY, Attenhofer Jost, C H, Soyka, R, Oxenius, A, Kretschmar, O, Valsangiacomo Buechel, ER, Greutmann, M, Weber, R, Keramida, K, Kouris, N, Kostopoulos, V, Karidas, V, Damaskos, D, Makavos, G, Paraskevopoulos, K, Olympios, CD, Eskesen, K, Olsen, NT, Fritz-Hansen, T, Sogaard, P, Cameli, M, Lisi, M, Righini, FM, Curci, V, Massoni, A, Natali, B, Maccherini, M, Chiavarelli, M, Massetti, M, Mondillo, S, Mabrouk Salem Omar, A, Ahmed Abdel-Rahman, M, Khorshid, H, Rifaie, O, Santoro, C, Santoro, A, Ippolito, R, De Palma, D, De Stefano, F, Muscariiello, R, Galderisi, M, Squeri, A, Censi, S, Baldelli, M, Grattoni, C, Cremonesi, A, Bosi, S, Saura Espin, D, Gonzalez Canovas, C, Gonzalez Carrillo, J, Oliva Sandoval, MJ, Caballero Jimenez, L, Espinosa Garcia, MD, Garcia Navarro, M, Valdes Chavarri, M, De La Morena Valenzuela, G, Ryu, SK, Shin, DG, Son, JW, Choi, JH, Goh, CW, Choi, JW, Park, JY, Hong, GR, Sklyanna, O, Yuan, L, Yuan, L, Planinc, I, Bagadur, G, Ljubas, J, Baricevic, Z, Skoric, B, Velagic, V, Bijnens, B, Milicic, D, Cikes, M, Gospodinova, M, Chamova, T, Guergueltcheva, V, Ivanova, R, Tournev, I, Denchev, S, Ancona, R, Comenale Pinto, S, Caso, P, Arenga, F, Coppola, MG, Calabro, R, Neametalla, H, Boitard, S, Hamdi, H, Planat-Benard, V, Casteilla, L, Li, Z, Hagege, AA, Mericskay, M, Menasche, P, Agbulut, O, Merlo, M, Stolfo, D, Anzini, M, Negri, F, Pinamonti, B, Barbati, G, Di Lenarda, A, Sinagra, G, Stolfo, D, Merlo, M, Pinamonti, B, Gigli, M, Poli, S, Porto, A, Di Nora, C, Barbati, G, Di Lenarda, A, Sinagra, G, Coppola, C, Piscopo, G, Cipresso, C, Rea, D, Maurea, C, Esposito, E, Arra, C, Maurea, N, Nemes, A, Kalapos, A, Domsik, P, Forster, T, Voilliot, D, Huttin, O, Vaugrenard, T, Schwartz, J, Sellal, J-M, Aliot, E, Juilliere, Y, Selton-Suty, C, Sanchez Millan, P J, Cabeza Lainez, P, Castillo Ortiz, J, Chueca Gonzalez, EM, Gheorghe, L, Fernandez Garcia, P, Herruzo Rojas, MS, Del Pozo Contreras, R, Fernandez Garcia, M, Vazquez Garcia, R, Rosca, M, Popescu, BA, Botezatu, D, Calin, A, Beladan, CC, Gurzun, M, Enache, R, Ginghina, C, Farouk, H, Al-Maimoony, T, Alhadad, A, El Serafi, M, Abdel Ghany, M, Poorzand, H, Mirfeizi, SZ, Javanbakht, A, center, Preventive Cardiovascular care research, center, Lupus Research, sciences, Mashhad university of medical, Tellatin, S, Famoso, G, Dassie, F, Martini, C, Osto, E, Maffei, P, Iliceto, S, Tona, F, Radunovic, Z, Steine, KS, Jedrzejewska, I, Braksator, W, Krol, W, Swiatowiec, A, Sawicki, J, Kostarska-Srokosz, E, Dluzniewski, M, Maceira Gonzalez, A M, Cosin-Sales, J, Diago, JL, Aguilar, J, Ruvira, J, Monmeneu, J, Igual, B, Lopez-Lereu, MP, Estornell, J, Olszanecka, A, Dragan, A, Kawecka-Jaszcz, K, Czarnecka, D, Scholz, F, Gaudron, PD, Hu, K, Liu, D, Florescu, C, Herrmann, S, Bijnens, B, Ertl, G, Stoerk, S, Weidemann, F, Krestjyaninov, M, Razin, VA, Gimaev, RH, Bogdanovic, Z, Burazor, I, Deljanin Ilic, M, Peluso, D, Muraru, D, Cucchini, U, Mihaila, S, Casablanca, S, Pigatto, E, Cozzi, F, Punzi, L, Badano, LP, Iliceto, S, Zhdanova, E, Rameev, VV, Safarova, AF, Moisseyev, SV, Kobalava, ZD, Magnino, C, Omede, P, Avenatti, E, Presutti, D, Losano, I, Moretti, C, Bucca, C, Gaita, F, Veglio, F, Milan, A, Bellsham-Revell, H, Bell, AJ, Miller, OI, Simpson, JM, Hwang, YM, Kim, GH, Jung, MH, Woo, GH, Medicine, Department of Internal, Hospital, St.Vincents, Korea, The Catholic University of, Suwon, Division of Cardiology, Repu, Driessen, MMP, Leiner, T, Schoof, PH, Breur, JMPJ, Sieswerda, GT, Meijboom, FJ, Bellsham-Revell, H, Hayes, N, Anderson, D, Austin, BC, Razavi, R, Greil, GF, Simpson, JM, Bell, AJ, Zhao, XX, Xu, XD, Qin, YW, Szmigielski, C A, Styczynski, G, Sobczynska, M, Placha, G, Kuch-Wocial, A, Ikonomidis, I, Voumbourakis, A, Triantafyllidi, H, Pavlidis, G, Varoudi, M, Papadakis, I, Trivilou, P, Paraskevaidis, I, Anastasiou-Nana, M, Lekakis, I, Kong, WILL, Yip, JAMES, Ling, LH, Milan, A, Tosello, F, Leone, D, Bruno, G, Losano, I, Avenatti, E, Sabia, L, Veglio, F, Zaborska, B, Baran, J, Pilichowska-Paszkiet, E, Sikora-Frac, M, Michalowska, I, Kulakowski, P, Budaj, A, Mega, S, Bono, MC, De Francesco, V, Castiglione, I, Ranocchi, F, Casacalenda, A, Goffredo, C, Patti, G, Di Sciascio, G, Musumeci, F, Kennedy, M, Waterhouse, DF, Sheahan, R, Foley, DF, Mcadam, BF, Ancona, R, Comenale Pinto, S, Caso, P, Arenga, F, Coppola, MG, Calabro, R, Remme, E W, Smedsrud, M K, Hasselberg, N E, Smiseth, O A, Edvardsen, T, Halmai, L, Nemes, A, Kardos, A, Neubauer, S, Degiovanni, A, Baduena, L, Dellera, G, Occhetta, E, Marino, P, Hotchi, J, Yamada, H, Nishio, S, Bando, M, Hayashi, S, Hirata, Y, Amano, R, Soeki, T, Wakatsuki, T, Sata, M, Lamia, B, Molano, LC, Viacroze, C, Cuvelier, A, Muir, JF, Lipczynska, M, Piotr Szymanski, PS, Anna Klisiewicz, AK, Lukasz Mazurkiewicz, LM, Piotr Hoffman, PH, Van T Sant, J, Wijers, SC, Ter Horst, IAH, Leenders, GE, Cramer, MJ, Doevendans, PA, Meine, M, Hatam, N, Goetzenich, A, Aljalloud, A, Mischke, K, Hoffmann, R, Autschbach, R, Sikora-Frac, M, Zaborska, B, Maciejewski, P, Bednarz, B, Budaj, A, Evangelista, A, Torromeo, C, Pandian, NG, Nardinocchi, P, Varano, V, Schiariti, M, Teresi, L, Puddu, PE, Storve, S, Dalen, H, Snare, SR, Haugen, BO, Torp, H, Fehri, W, Mahfoudhi, H, Mezni, F, Annabi, MS, Taamallah, K, Dahmani, R, Haggui, A, Hajlaoui, N, Lahidheb, D, Haouala, H, Colombo, A, Carminati, MC, Maffessanti, F, Gripari, P, Pepi, M, Lang, RM, Caiani, EG, Walker, JR, Abadi, S, Agmon, Y, Carasso, S, Aronson, D, Mutlak, D, Lessick, J, Saxena, A, Ramakrishnan, S, Juneja, R, Ljubas, J, Reskovic Luksic, V, Matasic, R, Pezo Nikolic, B, Lovric, D, Separovic Hanzevacki, J, Quattrone, A, Zito, C, Alongi, G, Vizzari, G, Bitto, A, De Caridi, G, Greco, M, Tripodi, R, Pizzino, G, Carerj, S, Ibrahimi, P, Jashari, F, Johansson, E, Gronlund, C, Bajraktari, G, Wester, P, Henein, MY, Kosmala, W, Marwick, TH, Souza, J R M, Zacharias, L G T, Geloneze, B, Pareja, J C, Chaim, A, Nadruz, W JR, Coelho, O R, Apostolovic, S, Stanojevic, D, Jankovic-Tomasevic, R, Salinger-Martinovic, S, Djordjevic-Radojkovic, D, Pavlovic, M, Tahirovic, E, Musial-Bright, L, Lainscak, M, Duengen, HD, group, CIBIS ELD study, Filipiak, D, Kasprzak, JD, and Lipiec, P

Abstract

Purpose: With the advent of percutaneous transcatheter device closures in congenital heart defects and the emergence of percutaneous left atrial appendage closure, there is an increasingly important role for echocardiographic guidance and control of device position and function. Disc occluder devices frequently present as an unexplained ‘figure-of-8’ on echocardiography. The aim of this study was to clarify this ‘figure-of-8’ display and to relate its morphology to transducer position and device type. Methods: A mathematical model was developed to resemble disc occluder geometry and to allow a numerical simulation of the echocardiographic appearance. In addition, we developed an in vitro set-up for echocardiographic analysis of various disc occluders and various transducer positions. Results: In the mathematical model of an epitrochoid curve (closely resembling disc occluder geometry) a ‘figure-of-8’ display is obtained when emphasizing points with tangent vector perpendicular to the direction of ultrasound waves. Decreasing imaging depth results in a more asymmetric ‘figure-of-8’, with small upper part and wide lower part. Clinical and in vitro data are in close agreement with these results (Figure 1). Furthermore a ‘figure-of-8’ display is only obtained in a coronal imaging position, and is similar for different commercially available disc occluder types. Conclusions: The ‘figure-of-8’ display in the ultrasound image of a disc occluder is an imaging artifact due to the specific ‘epitrochoidal’ geometry of a deployed device and its interaction with ultrasound waves. The morphology of the ‘figure-of-8’ depends on transducer position, i.e. imaging depth, and is similar for different device types. Figure 1 Impact of imaging depth

Published
2013
Full Text
View/download PDF

19. [The chronic hepatitis under pulmonary, extra-pulmonary and abdominal tuberculosis.]

Author

Aryamkina OL, Savonenkova LN, Ruzov VI, Midlenko VI, Gnoevy Kh VV, Razin VA, and Gamaev RK

Subjects
Humans, Multimorbidity, Tuberculosis, Gastrointestinal complications, Tuberculosis, Pulmonary complications, Hepatitis, Chronic complications, Tuberculosis complications
Abstract

The poly-morbidity is an actual problem of clinical medicine. The chronic hepatitis and tuberculosis are among widespread socially significant diseases while their relationship needs further investigation. The purpose of study is to analyze rate of occurrence, structure and clinic а chronic hepatitis taking course in comorbidity with tuberculosis of various localizations. The technique of continuous sampling was applied to carry out cohort randomized single-staged study analyzing rate structure and clinic of chronic hepatitis in 1189 patients with tuberculosis including pulmonary (n=1125), extra-pulmonary (n=24), abdominal (n-40) localizations. The chronic hepatitis is established in 45% of all cases and in half of cases out of them at the stage of exacerbation (53.2%) when the disease is presented by viral (59.6%) predominantly hepatitis C, alcoholic (25.7%), non-alcoholic (9.8%) and medicinal (4.9%) steatohepatits. The chronic hepatitis associates with pulmonary tuberculosis 3.4-1.7 times more often than with extra-pulmonary and abdominal tuberculosis. The chronic hepatitis is characterized by minimal and moderate activity of inflammation. The chronic hepatitis in case of abdominal tuberculosis manifests more expressed alterations of all laboratory syndromes of hepatitis. The medicinal hepatitis was established only in case of pulmonary tuberculosis. The chronic hepatitis С and B progresses in a comorbide way, is characterized by little symptoms, cytolysis with 2.3-2.8 standards of ALT, AST, minimal parenchymatous jaundice and cholestasis with activity of GGTP 2.86 of standards, mesenchymal inflammation in 3.1-3.4 times more often in case of its comorbidity with extra-pulmonary and abdominal tuberculosis. The alcoholic steatohepatitis is characterized by higher cytolysis, predominance of activity of AST over ALT, more expressed parenchymatous jaundice and cholestasis. The non-alcoholic steatohepatitis is characterized by poly-morbidity with diabetes mellitus type II also, cardiovascular pathology, steatosis of liver, the lowest parameters of markers of cytolysis, mesenchymal inflammation, jaundice, cholestasis and normal values of markers of hepatic cellular inadequacy. The medicinal hepatitis is characterized by increasing of asthenia, nausea, development of jaundice, skin itching, hepatomegaly,cytolysis, cholestasis, hyper-bilirubinemia against the background of specific poly-chemotherapy., Competing Interests: The authors declare no conflict of interest.

Published
2017
Full Text
View/download PDF

20. [The character of alterations of electrophysiological properties of myocardium in the patients with arterial hypertension associated with type 2 diabetes mellitus].

Author

Gimaev RKh, Ruzov VI, and Razin VA

Subjects
Female, Humans, Male, Middle Aged, Diabetes Mellitus, Type 2 complications, Heart physiopathology, Hypertension pathology, Hypertension physiopathology, Myocardium pathology
Abstract

The present study was designed to elucidate the character and severity of electrophysiological disturbances in the patients presenting with arterial hypertension (AH) associated with type 2 diabetes mellitus (DM). It included 55 patients with AH (mean age 50.4 +- 4.7 years) allocated to two groups. Group 1 was comprised of 25 patients with arterial hypertension and concomitant type 2 diabetes mellitus. Group 2 (n = 30) consisted of the patients with AH in the absence of diabetes. All the patients were examined using 12-lead ECG and high-resolution ECG (HR-ECG) supplemented by the analysis of late ventricular potentials (LVP) and cardiac rhythm variability (CRV). The study has demonstrated that diabetes mellitus in the patients suffering AH aggravates the disturbances in electrophysiological properties of myocardium compared with the patients having no metabolic disorders. These disturbances include changes of both repolarization and depolarization of myocardium. The patients with AH and concomitant diabetes mellitus had much higher values of dispersion and duration of QT-interval. Analysis of the results of HR-ECG in the two groups has revealed a significantly higher occurrence of late ventricular potentials in the patients with AH and concomitant type 2 DM (52% and 27% respectively; x2 = 4.43, p = 0.03). Analysis of rhythmograms showed progressive deterioration of temporal and spectral characteristics of CRV in the group of patients with AH and concomitant type 2 DM. Moreover; these patients were characterized by the reduction of sympathetic and parasympathetic influences on myocardium.

Published
2012

21. [Effect of lipid metabolism disturbances on electrophysiologic heart remodeling in patients with hypertensive disease].

Author

Gimaev RKh, Ruzov VI, Razin VA, Boluchevskiĭ DN, Verushkina AS, and Siapukova AA

Subjects
Adult, Aged, Blood Pressure physiology, Dyslipidemias blood, Dyslipidemias complications, Female, Follow-Up Studies, Humans, Hypertension blood, Hypertension physiopathology, Male, Middle Aged, Risk Factors, Dyslipidemias physiopathology, Electrocardiography, Heart Rate physiology, Hypertension complications, Lipids blood, Ventricular Remodeling physiology
Abstract

The aim of the study was to evaluate effect of disturbed lipid metabolism on dispersion of QT interval, signal-averaged ECG characteristics, and cardiac rhythm variability as indicators of electrophysiological remodeling of myocardium in patients with HD. The study included 111 patients aged 30-73 (mean 51.4 +/- 10.7) years with stage I-II HD. All of them were examined by 12-lead ECG and high-resolution ECG with the analysis of late atrial (LAP) and ventricular (LVP) potentials. Cardiac rhythm variability (CRV) was evaluated. Analysis of standard ECG parameters depending on lipid metabolism revealed significantly higher dispersion of corrected QT interval in patients with hypercholesterolemia. High-resolution ECG showed LAP in 16 (25%) patients with hypercholesterolemia compared with 11% among patients with normal serum cholesterol (chi2 = 2.8; p = 0.042). LVPs were documented in 41, 34, 31, and 26% of the patients with high, moderately elevated, low, and normal serum cholesterol respectively. The difference was confirmed by respective changes of certain parameters of high-resolution ECG in the same patients.

Published
2009

22. [Correction of ventricular late potentials with drug and non-drug methods in patients with essential hypertension].

Author

Gimaev RKh, Rukhov VI, Drapova DP, Razin VA, Iudina EE, Auadi KhB, and Sharangin SA

Subjects
Adult, Aged, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Calcium Channel Blockers therapeutic use, Delayed-Action Preparations, Drug Therapy, Combination, Electrocardiography, Female, Humans, Hypertension diagnosis, Lisinopril therapeutic use, Male, Middle Aged, Nifedipine therapeutic use, Ozone metabolism, Sodium Chloride metabolism, Sodium Chloride therapeutic use, Ventricular Dysfunction drug therapy, Hypertension epidemiology, Hypertension physiopathology, Ventricular Dysfunction epidemiology, Ventricular Dysfunction therapy
Abstract

The aim of the work was to evaluate the effects of drug and non-drug methods of treatment of patients with essential hypertension (EH) on ventricular late potentials (VLP). One hundred and thirteen patients with I to II stage EH aged 30 to 73 (mean age 53 +/- 9.7 years) were included in the study. VLP were registered by recording signal-averaged ECG (SA-ECG) before and after treatment with antihypertensive preparations (lisinopril, nifedipine) and intravenous ozone therapy. VLP were detected in 34 (30%) of the EH patients. The study found a decrease in the frequency of VLP detection from 40% (8 patients) to 10% (2 patients) after therapy with the ACE inhibitor lisinopril. In the group of patients who received monotherapy with the calcium antagonist nifedipine the number of subjects with VLP before and after the treatment was the same, 3 patients or 20%. In the group receiving bi-component therapy with lisinopril, an ACE inhibitor, and nifedipine, a calcium antagonist, the number of patients with VLP fell from 4 subjects (28.6%) to 1 subject. These data were confirmed with significant SA-ECG parameters. The study also revealed that ozone therapy as a part of complex treatment of EH improved SA-ECG parameters, which manifested by a decrease in VLP from 29.7% to 14.1%.

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results